Pediatric meningococcocal meningitis in the acute phase: how much does it cost?

Elena Bozzola, Stefano Guolo, Enea Bonci, Chiara Rossetti, Mauro Bozzola, Massimiliano Raponi, Alberto Villani

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Meningococcal meningitis (MM) is known to be responsible of high cost for the Public Health Administration. Aim of the work is to calculate the costs for the hospitalization of pediatric patients affected by MM.

METHODS: We calculate the costs for the hospitalization of pediatric patients affected by MM in the acute phase (HAP) over a nine year period. We performed a MEDLINE search to verify the cost of MM HAP reported in other studies.

RESULTS: At Bambino Gesù Children Hospital, the median cost of HAP was of 12,604 euro (range from 9203 to 35,050 euro). Comparing our data with the previous studies, we find out similar results of approximately 16,750 euro (range 12,000-20,000 euro).

DISCUSSION: Despite the relative rarety of the disease, MM is associated to direct high cost of HAP.

CONCLUSIONS: Hospital costs are an important end-point in health economic evaluation of the disease and may be useful to policy makers and health economists to understand the potential benefit of improving meningococcal vaccination programmes.

Original languageEnglish
Pages (from-to)25
JournalItalian Journal of Pediatrics
Volume45
Issue number1
DOIs
Publication statusPublished - Feb 13 2019

Fingerprint Dive into the research topics of 'Pediatric meningococcocal meningitis in the acute phase: how much does it cost?'. Together they form a unique fingerprint.

Cite this